Neoadjuvant ADCs With CL2A Linkers for Resistant Cancers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for more effective forms of immunoconjugate-based neoadjuvant cancer therapy, particularly for cancers that are resistant to standard anti-cancer treatments such as triple-negative breast cancer (TNBC), as existing therapies like anti-HER2 antibodies are ineffective in TNBC and other aggressive forms of cancer.
Innovation Solution
The use of antibody-drug conjugates (ADCs) with relatively non-toxic drugs like camptothecins (e.g., SN-38) or anthracyclines (e.g., P2PDOX) linked via a CL2A linker, allowing extracellular and intracellular drug release, enabling higher dosages and improved therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard anti-cancer therapies are used, then treatment is effective for sensitive cancers, but they are ineffective for resistant cancers such as triple-negative breast cancer
Solution Approach 1:
The patent changes the chemical parameters of the therapy by using antibody-drug conjugates with modified drug linkers (CL2A, CL2B, CL2C) that enable intracellular cleavage and drug release. This parameter change allows the therapy to overcome resistance mechanisms in TNBC and other resistant cancers while maintaining effectiveness in sensitive cancers
Solution Approach 2:
The patent creates composite therapeutic agents by conjugating antibodies (such as anti-TROP-2, anti-CEACAM5, or anti-EGFR antibodies) with cytotoxic drugs (camptothecins like SN-38 or anthracyclines like P2PDox) through specialized linkers. This composite structure combines the targeting capability of antibodies with the cytotoxic effect of drugs, enabling effective treatment of resistant cancers
2Productivity
If higher dosages of ADCs are administered to improve therapeutic efficacy, then tumor shrinkage is enhanced, but toxicity increases
Solution Approach 1:
The patent employs preliminary targeting action where antibodies in the ADC conjugates first bind to tumor-associated antigens on cancer cell surfaces before drug release. This preliminary targeting ensures that the cytotoxic drugs are delivered specifically to tumor cells, allowing higher dosages to be administered while minimizing off-target toxicity to healthy tissues
Solution Approach 2:
The patent uses antibody-drug conjugates as intermediary carriers that transport cytotoxic drugs from the bloodstream to tumor cells. The antibody component acts as a mediator that directs the drug to the target, enabling higher drug dosages to reach the tumor while reducing systemic toxicity through selective delivery
Data Source
AI summary
The present invention concerns improved methods and compositions for neoadjuvant use of antibody-drug conjugates (ADCs) in cancer therapy, preferably ADCs comprising an anthracycline or camptothecin, more preferably SN-38 or pro-2-pyrrolinodoxorubicin (P2PDox). The ADC is administered as a neoadjuvant, prior to treatment with a standard anti-cancer therapy such as surgery, radiation therapy, chemotherapy, or immunotherapy. Neoadjuvant use of the ADC substantially improves the efficacy of standard anti-cancer therapy and may debulk a primary tumor or eliminate micrometasteses. In most preferred embodiments, neoadjuvant ADC in combination with a standard anti-cancer therapy is successful in treating cancers that are resistant to standard treatments, such as triple-negative breast cancer (TNBC).